Antibiotics Effective Against MRSA

Introduction to MRSA Treatment

The Infectious Diseases Society of America recommends vancomycin as the standard intravenous option for severe MRSA skin and soft tissue infections, while linezolid, trimethoprim-sulfamethoxazole (TMP-SMX), and doxycycline are preferred oral agents for less severe cases 1, 2, 3

Vancomycin is the traditional standard for severe MRSA infections, including bacteremia, endocarditis, and complicated skin/soft tissue infections, as recommended by the Infectious Diseases Society of America 1, 4, 5, 3
Daptomycin is non-inferior to vancomycin for MRSA bacteremia, right-sided endocarditis, and complicated skin/soft tissue infections, with a dosage of 10 mg/kg/dose IV once daily 2, 3
Linezolid is superior to vancomycin for skin/soft tissue infections, with better clinical cure rates (OR 1.41), and is recommended by the Infectious Diseases Society of America 1, 2, 3, 6
Ceftaroline is a broad-spectrum cephalosporin with MRSA activity, non-inferior to vancomycin for skin/soft tissue infections, as recommended by the Infectious Diseases Society of America 2, 3

Linezolid is the recommended oral agent for community-acquired MRSA skin/soft tissue infections, with excellent bioavailability, and is recommended by the Infectious Diseases Society of America 2, 5, 3, 7
Trimethoprim-sulfamethoxazole (TMP-SMX) is effective for uncomplicated infections, supported by observational studies and randomized trials, and is recommended by the Infectious Diseases Society of America 2, 5, 3
Doxycycline or minocycline are tetracyclines with proven efficacy, and minocycline may be more reliable when doxycycline or TMP-SMX fails, as recommended by the Infectious Diseases Society of America 2, 5, 3

Uncomplicated skin/soft tissue infections should be treated for 5-10 days, as recommended by the Infectious Diseases Society of America 7
Complicated skin/soft tissue infections should be treated for 7-14 days based on clinical response, as recommended by the Infectious Diseases Society of America 2, 3, 7

For hospitalized children with complicated MRSA skin/soft tissue infections, vancomycin is recommended first-line by the Pediatric Infectious Diseases Society 5
For diabetic foot infections with suspected/confirmed MRSA, mild infections can be treated with TMP-SMX, while moderate to severe infections require linezolid, daptomycin, or vancomycin, as recommended by the Infectious Diseases Society of America 4
For necrotizing fasciitis with MRSA, treatment should include vancomycin or linezolid plus piperacillin-tazobactam or a carbapenem, as recommended by the Infectious Diseases Society of America 1, 4

Vancomycin has limitations, including rising MICs within the susceptible range, which can reduce its effectiveness, as noted by the Infectious Diseases Society of America 1, 4
TMP-SMX and tetracyclines are effective against MRSA, but their activity against beta-hemolytic streptococci is not well-defined, and dual coverage may be needed, as recommended by the Infectious Diseases Society of America 5
Rifampin monotherapy should be avoided, as resistance develops rapidly, and it should only be used in combination with another active agent, as recommended by the Infectious Diseases Society of America 5